Vitamin B12 levels during prolonged treatment with proton pump inhibitors

Journal of Clinical Gastroenterology

Volumn 30, Issue 1, 2000, Pages 29-33

  Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Absorption; Cobalamin; Lansoprazole; Omeprazole

Indexed keywords

CYANOCOBALAMIN; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; PROTON PUMP;

ACHLORHYDRIA; CYANOCOBALAMIN DEFICIENCY; DRUG INDUCED DISEASE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; ZOLLINGER ELLISON SYNDROME; ABSORPTION; BLOOD; DRUG ANTAGONISM; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SECRETION; STOMACH; STOMACH ACID; TIME;

ABSORPTION; GASTRIC ACID; HUMANS; PROTON PUMPS; STOMACH; TIME FACTORS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 0033621625     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200001000-00006     Document Type: Review

References (29)

1. Allen RH, Seetharam B, Podell ER, Alpers DH. Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency. J Clin Invest 1978;61:47-54.
2. Marcoulis G, Parmentier Y, Nicolas JP, et al. Cobalamin malabsorption due to non-degradation of R proteins in the human intestine. Inhibited cobalamin malabsorption in exocrine pancreatic insufficiency. J Clin Invest 1980;66: 430-40.
3. Kolhouse JF, Allen RH. Absorption, plasma transport, and cellular retention of cobalamin and analogues in the rabbit. J Clin Invest 1977;60:1381-92.
4. Mathan VI, Babior RM, Donaldson RM Jr. Kinetics of the attachment of intrinsic factor-bound cobamides to ileal receptors. J Clin Invest 1974;54: 598-608.
5. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Alimentary Pharmacol Therap 1992;6:399-406.
6. Schron CM. Vitamins and minerals. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of gastroenterology, 2nd ed. Philadelphia: J. B. Lippincott: 1995:467-84.
7. Howden CW, Castell DO, Cohen S, Freston JW, Orlando RC, Robinson M. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intent Med 1995;155:1465-71.
8. Yeomans ND, Tulassay Z, Juhsz L, et al. A comparison of omeprazole and ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
9. Hawkey CJ, Karrasch JA, Szczepazski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
10. Lloyd-Davies KA, Rutgerson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Alimentary Pharmacol Therap 1988;2:13-32.
11. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97: 827-36.
12. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:394-404.
13. 12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30.
14. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6.
15. Kittang E, Aadland E, Schjonsby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 1985;26:594-98.
16. Kittang E, Aadland E, Schjonsby H, Rohss K. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scand J Gastroenterol 1987;22:156-60.
17. Kittang E, Schjonsby H. Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. Scand J Gastroenterol 1987;22:1031-7.
18. 12). Ann Intern Med 1994;120:21-215.
19. 12 absorption. J Am Coll Nutr 1994;13:584-91.
20. Schenk BE, Festen HPM, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SGM. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Alimentary Pharmacol Therap 1996; 10:541-45.
21. Data on file, TAP Pharmaceuticals Inc., Deerfield, IL.
22. 12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92.
23. Bellou A, Aimone-Gastin I, De Korwin JD, et al. Cobalamin deficiency with megaloblastic anemia in one patient under long-term omeprazole therapy. J Intern Med 1996;240:161-4.
24. Van Herwaarden MA, Samson M, van Nispen CHM, Smout AJPM. H. pylori eradication reduces the effect of lansoprazole but not that of ranitidine on intragastric pH. Gastroenterology 1998;114:A321 (abstract).
25. Verdu EF, Armstrong D, Frazer R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
26. Verdu EF, Armstrong D, Idstrom J-P, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
27. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
28. Genta RM. Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy. Gastroenterology 1997; 113(suppl 1):S51-S55.
29. IMS audited data, 1998.